JP2009544280A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544280A5
JP2009544280A5 JP2009519713A JP2009519713A JP2009544280A5 JP 2009544280 A5 JP2009544280 A5 JP 2009544280A5 JP 2009519713 A JP2009519713 A JP 2009519713A JP 2009519713 A JP2009519713 A JP 2009519713A JP 2009544280 A5 JP2009544280 A5 JP 2009544280A5
Authority
JP
Japan
Prior art keywords
gene
deletion
cfhr1
gene product
cfhr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009519713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544280A (ja
JP5431151B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/073514 external-priority patent/WO2008008986A2/en
Publication of JP2009544280A publication Critical patent/JP2009544280A/ja
Publication of JP2009544280A5 publication Critical patent/JP2009544280A5/ja
Application granted granted Critical
Publication of JP5431151B2 publication Critical patent/JP5431151B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009519713A 2006-07-13 2007-07-13 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬 Active JP5431151B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83101806P 2006-07-13 2006-07-13
US60/831,018 2006-07-13
US84007306P 2006-08-23 2006-08-23
US60/840,073 2006-08-23
PCT/US2007/073514 WO2008008986A2 (en) 2006-07-13 2007-07-13 Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration

Publications (3)

Publication Number Publication Date
JP2009544280A JP2009544280A (ja) 2009-12-17
JP2009544280A5 true JP2009544280A5 (enExample) 2010-09-02
JP5431151B2 JP5431151B2 (ja) 2014-03-05

Family

ID=38924245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009519713A Active JP5431151B2 (ja) 2006-07-13 2007-07-13 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬

Country Status (11)

Country Link
US (4) US7867727B2 (enExample)
EP (3) EP2479284B1 (enExample)
JP (1) JP5431151B2 (enExample)
AT (1) ATE551350T1 (enExample)
AU (1) AU2007272335B2 (enExample)
CA (1) CA2659392A1 (enExample)
DK (1) DK2447275T3 (enExample)
IL (1) IL196319A0 (enExample)
NZ (1) NZ574046A (enExample)
SG (1) SG173371A1 (enExample)
WO (1) WO2008008986A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745389B2 (en) * 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
US20080146501A1 (en) * 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
MX2009000909A (es) * 2006-07-26 2009-02-04 Univ Yale Diagnostico y tratamiento de degeneracion macular relacionada con la edad.
WO2009059317A2 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
JP2011510297A (ja) * 2008-01-18 2011-03-31 バトリックス・メディカル・インコーポレイテッド 動脈瘤のための診断バイオマーカー
DE102008049136B4 (de) * 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
JP2012533562A (ja) * 2009-07-16 2012-12-27 グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド 治療法
US20120190578A1 (en) * 2009-08-06 2012-07-26 Washington University Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes
WO2011029954A2 (de) * 2009-09-14 2011-03-17 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen
JP5706612B2 (ja) * 2009-12-28 2015-04-22 学校法人 埼玉医科大学 加齢黄斑変性症易罹患性の判定マーカー並びに判定方法及び判定キット
US20120202708A1 (en) * 2010-10-14 2012-08-09 Sequenom, Inc. Complement factor h copy number variants found in the rca locus
US9598733B2 (en) 2011-02-17 2017-03-21 The Trustees Of Columbia University In The City Of New York Methods for identifying subjects with a genetic risk for developing IgA nephropathy
KR20140074258A (ko) * 2011-04-29 2014-06-17 유니버시티 오브 유타 리서치 파운데이션 보체-매개된 질환의 발생을 예측하는 방법들
JP2013064616A (ja) * 2011-09-15 2013-04-11 Osaka Univ 高度動脈硬化を発症している可能性を検出する方法およびその利用
WO2013150132A2 (de) * 2012-04-05 2013-10-10 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnostik und beurteilung von schlaganfällen
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
EP2962106A1 (en) * 2013-02-26 2016-01-06 Roche Diagnostics GmbH Agents, kits and methods for complement factor h-related protein 1 detection
WO2014169294A1 (en) 2013-04-12 2014-10-16 The Trustees Of Columbia University In The City Of New York Mutations in dstyk cause dominant urinary tract malformations
WO2014194213A1 (en) * 2013-05-30 2014-12-04 University Of Iowa Research Foundation Specific complement proteins and efficacy of antibody therapy
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
US11072661B2 (en) 2015-12-23 2021-07-27 Sorbonne Universite Agents that inhibit the binding of CFH to CD11 b/CD18 and uses thereof
US11142548B2 (en) 2016-05-10 2021-10-12 Sorbonne Universite Agents that activate CD47 and their use in the treatment of inflammation
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
JP7467355B2 (ja) * 2018-05-10 2024-04-15 コンプリメント・セラピューティクス・リミテッド 黄斑変性症を評価するための方法
WO2020019002A1 (en) 2018-07-20 2020-01-23 University Of Utah Research Foundation Gene therapy for macular degeneration
DE102018120016B4 (de) * 2018-08-16 2020-09-03 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- Modulatoren der Funktion von Faktor H-verwandtem Protein 1 und deren Verwendungen in der Kontrolle von Entzündung
WO2020180147A2 (ko) * 2019-03-07 2020-09-10 (주)레티마크 나이관련 황반변성 진단용 복합 마커 및 이의 용도
CA3136119A1 (en) 2019-04-10 2020-10-15 University Of Utah Research Foundation Htra1 modulation for treatment of amd
JP2022553309A (ja) * 2019-10-22 2022-12-22 アプライド ジェネティック テクノロジーズ コーポレイション 加齢黄斑変性ならびに他の眼疾患および障害の治療のためのアデノ随伴ウイルス（ａａｖ）ベクター
EP4214515A1 (en) * 2020-09-16 2023-07-26 Complement Therapeutics Limited Complementome assay
GB202107586D0 (en) * 2021-05-27 2021-07-14 Complement Therapeutics Ltd Inhibitory nucleic acids for Factor H family proteins
WO2026101913A1 (en) * 2024-11-05 2026-05-15 Alnylam Pharmaceuticals, Inc. Sirnas targeting complement factor h-related (cfhr) gene transcripts and methods of use

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
US5037746A (en) 1986-12-03 1991-08-06 University Patents, Inc. RNA ribozyme polymerases, and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
JP2897959B2 (ja) 1988-05-20 1999-05-31 エフ．ホフマン―ラ ロシュ アクチェンゲゼルシャフト 固定化された配列特異的プローブ
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US20020032313A1 (en) * 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
EP0512733A2 (en) 1991-05-03 1992-11-11 Washington University Modified complement system regulator
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CA2134552A1 (en) 1992-04-27 1993-11-11 George D. Sorenson Detection of gene sequences in biological fluids
DE69333930T8 (de) 1993-01-22 2007-02-22 The Regents Of The University Of Colorado, Boulder Lokalisierung von therapeutischen mitteln
US5667969A (en) 1993-11-12 1997-09-16 University Research Corporation Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6706471B1 (en) 1996-01-24 2004-03-16 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
GB9710475D0 (en) 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DK1068311T3 (da) 1998-04-08 2011-08-08 Commw Scient Ind Res Org Fremgangsmåder og midler til opnåelse af modificerede fænotyper
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
AU3704500A (en) 1999-02-19 2001-01-22 University Of Iowa Research Foundation, The Diagnostics and therapeutics for arterial wall disruptive disorders
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
DK1287364T3 (da) 2000-04-29 2009-03-02 Univ Iowa Res Found Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
US6632606B1 (en) 2000-06-12 2003-10-14 Aclara Biosciences, Inc. Methods for single nucleotide polymorphism detection
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
AUPR604101A0 (en) 2001-06-29 2001-07-26 Unisearch Limited Aptamers
WO2003016470A2 (en) 2001-08-10 2003-02-27 University Of Virginia Patent Foundation Enhancing the efficacy of immunotherapies by supplementing with complement
CA2588270A1 (en) * 2004-11-18 2006-06-15 Yale University Methods and compositions for treating ocular disorders
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
US7695909B2 (en) 2005-06-08 2010-04-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Susceptibility genes for age-related maculopathy (ARM) on chromosome 10q26
CN101331235A (zh) 2005-10-11 2008-12-24 耶鲁大学 与黄斑变性相关的基因
JP2009514534A (ja) 2005-11-02 2009-04-09 アメリカ合衆国 加齢黄斑変性の識別および検査のための発展した方法（ｍｅｒｔ−ａｒｍｄ）
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
US20080146501A1 (en) 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
GB0611606D0 (en) * 2006-06-13 2006-07-19 Univ Belfast Protection against and treatment of age related macular degeneration

Similar Documents

Publication Publication Date Title
JP5431151B2 (ja) 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬
Kerlin et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia
EP3811972B1 (en) Combination therapy for treatment of atherosclerosis
JP2007506426A5 (enExample)
Zorzetto et al. Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis
Zepp et al. TRAF4-SMURF2–Mediated DAZAP2 degradation is critical for IL-25 signaling and allergic airway inflammation
CN105431549A (zh) 癌症中的tert(端粒酶逆转录酶)基因启动子突变
JP2003508022A5 (enExample)
Ngo et al. The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas
EP2855516B1 (en) Inflammation-enabling polypeptides and uses thereof
JP2014513289A (ja) ＩＦＮβに対する治療応答性を予測するバイオマーカーおよびその使用
WO2012107580A1 (en) In vitro diagnosis method for predicting a predisposition to cardiomyopathy
US20180258484A1 (en) Inflammation-enabling polypeptides and uses thereof
JP4779115B2 (ja) 早期肺癌の術後予後検査方法
JP2020530978A (ja) Ｈｌａ−ｇ転写物およびアイソフォームおよびそれらの使用
JP2009515183A (ja) 新たなタンパク質アイソフォーム及びその使用
JP2018504909A5 (enExample)
WO2016122865A1 (en) Compositions and methods for treating age-related diabetes and related disorders
US20170072071A1 (en) Inflammation-enabling polypeptides and uses thereof
Asselta et al. Missense or splicing mutation? The case of a fibrinogen Bβ-chain mutation causing severe hypofibrinogenemia
Chen et al. von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study
JP2006516888A5 (enExample)
US20160326585A1 (en) Inflammation-enabling polypeptides and uses thereof
CN108752452B (zh) Sars及其突变体的应用
JP4471803B2 (ja) 全身性エリテマトーデス患者血液細胞で発現亢進している遺伝子群、およびその利用